Founded in 2014 in Montreal, Canada, Nanora Pharma leads the way in nanomedicine and siRNA-based therapies. The NORAfecta Platform and NORA therapy were pioneered by Professor Satya Prakash and his research team in the Faculty of Medicine at McGill University, leveraging polymeric hydrogel nanocarrier targeted delivery systems to enhance therapy bioavailability, selectivity, and efficacy while reducing toxicity.
Nanora Pharma integrates molecular biology, nanotechnology, and pharmacology to develop RNA-based precision medicine. Our work targets some of the most challenging oncological, inflammatory, and neurodegenerative diseases.
To be a global leader in nanotechnology-driven oncology and cancer therapeutic delivery systems, setting new standards in precision medicine and targeted cancer therapeutics.
To drive innovation in siRNA-based cancer therapy by developing next-generation nanoparticle-based cancer treatments that enhance therapeutic outcomes and patient quality of life. We are committed to:
We harness the power of RNAi and nanomedicine to develop innovative cancer treatment delivery systems.
Our treatments undergo comprehensive preclinical studies, ensuring efficacy and safety.
We design therapies that prioritize biocompatibility, controlled release, and minimal systemic toxicity.
We adhere to the highest standards in scientific integrity, safety, and regulatory compliance.
Nanora Pharma is at the forefront of pharmaceutical innovation, dedicated to developing advanced treatments that improve lives worldwide. Our passion for science and commitment to health drive us to deliver groundbreaking solutions for today’s medical challenges.
